Pharmacoeconomics: Open Access

Mike Baldwin

Publications

• Research Article
  Economic Evaluation of Omalizumab in the Treatment of Severe AllergicAsthma in Adult Patients in Greece: A Cost Effectiveness Analysis ofClinical Trial and Real-Life Data
  Author(s): Venkateshwarlu Sonathi, Magdalini Hatzikou, Mary Geitona, Mike Baldwin, Elena Panitti and Nikolaos SiafakasVenkateshwarlu Sonathi, Magdalini Hatzikou, Mary Geitona, Mike Baldwin, Elena Panitti and Nikolaos Siafakas
  
  Background: Severe asthma is a major cause of morbidity and mortality around the world, associated with a heavy societal burden. The aim of this study was to evaluate the economic value of omalizumab in the treatment of adult patients with severe asthma in Greece, from a societal perspective, based on both data collected via a clinical trial and data from a prospective observational study with real-world evidence (RWE) using a simulation model. Method: A Markov cohort model was developed in Microsoft Excel to compare the costs and outcomes of omalizumab plus standard therapy (ST) versus ST alone. The time horizon was that of a lifetime. Costs and health outcomes were discounted annually at 3.5%. A primary analysis was based on clinical data from the INNOVATE trial, and a secondary analysis, was based on recently published real-world evidence on.. Read More»
  DOI: 10.4172/2472-1042.1000103

  Abstract PDF